Trial
NCT00855972
Low Dose Naltrexone for the Treatment of Juvenile Primary Fibromyalgia Syndrome
UnknownWITHDRAWNREGULATORYConfidence: HIGH
Sponsor
Stanford University
Collaborators
—
Condition
Fibromyalgia
Intervention
Low Dose Naltrexone
Why stopped
The FDA IND application is paused due to additional required testing. The IRB protocol was closed prior to research starting.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-12-11